Related references
Note: Only part of the references are listed.Association of Hyaluronic Acid Family Members (HAS1, HAS2, and HYAL-1) With Bladder Cancer Diagnosis and Prognosis
Mario W. Kramer et al.
CANCER (2011)
Assessing the Clinical Benefit of Nuclear Matrix Protein 22 in the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer and Negative Cytology
Shahrokh F. Shariat et al.
CANCER (2011)
IS IT TIME TO RE-DESIGN THE HAEMATURIA CLINIC?
Hugh Mostafid et al.
BJU INTERNATIONAL (2010)
Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy
Dinesh K. Ahirwar et al.
BIOMARKERS (2009)
Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection
Yair Lotan et al.
BJU INTERNATIONAL (2009)
Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker
Yair Lotan et al.
JOURNAL OF UROLOGY (2009)
Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease
Bruce A. Julian et al.
PROTEOMICS CLINICAL APPLICATIONS (2009)
Genetic Association of Monocyte Chemoattractant Protein 1 (MCP-1)-2518 Polymorphism in Mexican Patients With Transitional Cell Carcinoma of the Bladder
Luis Gabriel Vazquez-Lavista et al.
UROLOGY (2009)
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44
Roozbeh Golshani et al.
CANCER RESEARCH (2008)
Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase Species
Roopali Roy et al.
CLINICAL CANCER RESEARCH (2008)
Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine
Sanaa Eissa et al.
EUROPEAN UROLOGY (2007)
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
Matilde Todaro et al.
CELL STEM CELL (2007)
Urine proteomics: the present and future of measuring urinary protein components in disease
Jonathan Barratt et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
Human body fluid proteome analysis
Shen Hu et al.
PROTEOMICS (2006)
Discovery of urinary biomarkers
Trairak Pisitkun et al.
MOLECULAR & CELLULAR PROTEOMICS (2006)
Molecular markers in bladder cancer: A critical appraisal
Badrinath R. Konety
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Soluble Fas - A promising novel urinary marker for the detection of recurrent superficial bladder cancer
RS Svatek et al.
CANCER (2006)
Prediction of extravesical disease by preoperative serum markers in patients with clinically organ confined invasive bladder cancer
D Margel et al.
JOURNAL OF UROLOGY (2006)
Plasma C-reactive protein and risk of cancer: A prospective study from Greece
D Trichopoulos et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Detection of immune responses against urinary bladder cancer in sentinel lymph nodes
P Marits et al.
EUROPEAN UROLOGY (2006)
The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins
Jun Adachi et al.
GENOME BIOLOGY (2006)
Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival
D Leibovici et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Development of a high-throughput automated analyzer using biochip array technology
SP FitzGerald et al.
CLINICAL CHEMISTRY (2005)
Complement factor H as a marker for detection of bladder cancer
ZZ Cheng et al.
CLINICAL CHEMISTRY (2005)
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins
C Conticello et al.
JOURNAL OF IMMUNOLOGY (2004)
Thrombomodulin-protein C-EPCR system - Integrated to regulate coagulation and inflammation
M Van de Wouwer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Low IL-1α a expression in bladder cancer tissue and survival
M Seddighzadeh et al.
EUROPEAN UROLOGY (2003)
Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative
PM Bossuyt et al.
CLINICAL CHEMISTRY (2003)
The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration
PM Bossuyt et al.
CLINICAL CHEMISTRY (2003)
Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas
F Monier et al.
EUROPEAN UROLOGY (2002)
Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer
M Sánchez-Carbayo et al.
JOURNAL OF UROLOGY (2001)